Why is Amgen stock up 3.3% today?

Traders Union
All News
Stocks
Amgen surges 3.36% today on strength

Highlights

Amgen attracted major institutional investment in the third quarter, supported by strong annual revenue of $36.75 billion and net profit of $7.71 billion.
Positive Phase 3 clinical trial data for autoimmune therapies and the MariTide program led UBS to raise its price target and sustained consistent dividend increases.
Shares of Amgen trade near $440.52 with strong bullish momentum, an 80% probability of further gains, and expected movement between $430.81 to $450.23 in the next five days.

Major stake increases as late-stage trial success boosts confidence

Amgen attracted significant institutional investment during the third quarter, with several major firms increasing their stakes according to recent SEC filings. The company reported annual revenue of $36.75 billion and a net profit of $7.71 billion, supported by successful late-stage clinical trials for its autoimmune therapies and the MariTide program. UBS raised its price target following the positive second-quarter results and encouraging Phase 3 trial data for dazodalibep. Amgen has also maintained a record of increasing dividends and strong cash flow that supports continued payouts.

Anton Kharitonov, expert at Traders Union, notes that Amgen’s recent rally is driven by hype over late-stage clinical trial results and heavy institutional flows. He sees the technical setup as overextended, with key oscillators signaling a strong risk of short-term exhaustion. Kharitonov is wary of the low intraday volatility, which may mask latent downside if momentum fades. He points to the major support at $437.19 as the first defense — a break here could quickly unravel recent gains. "I view current levels as vulnerable to correction, and would remain defensive unless support holds decisively."

Viktoras Karapetjanc, expert at Traders Union, sees strong upside for Amgen after its decisive clinical trial success and robust institutional backing. He highlights the bullish structure built on solid fundamentals — rising dividends, improving revenue, and upbeat analyst calls reinforce positive sentiment. Karapetjanc believes these drivers set the stage for further growth, especially if resistance at $450.23 is cleared. "Confidence remains high — the market offers multiple setups, and I expect the bullish momentum to continue toward new highs."

Jainam Mehta, market strategist, evaluates Amgen’s tight range and strong trend above all major moving averages. He stresses that the overbought technical signals warrant caution for momentum chasers, while noting potential for a tactical breakout above $450.23. Mehta suggests closely watching price action near $437.19 for early signs of reversal. "If a breakout fails and sellers emerge near resistance, a mean-reversion setup could be in play."

Persistent upward momentum as all indicators signal strong buying

Amgen is trading above its 20-day, 50-day, and 200-day moving averages at $408.36, $413.92, and $367.85 respectively, confirming consistent bullish pressure across short, medium, and long-term trends. The nearest levels are a support at $437.19 and a resistance at $450.23, with the Ichimoku Kijun at $401.21 reinforcing the positive trend backdrop. Momentum signals remain firm: the Moving Average Convergence Divergence (MACD) indicates a buy, and the Average Directional Index (ADX) remains neutral. The Relative Strength Index (RSI) is at 59.88 (buy), while the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power (BBP) all register overbought conditions, with BBP confirming strong buyer dominance intraday. The stock is trading near its session high in a very tight range, and intraday volatility stands at just 0.08%. There is strong momentum and strength toward highs, though several oscillators warn of stretched conditions.

Earlier, analysts noted that Amgen’s strong technical performance and positive late-stage clinical data positioned the stock for further strength pending confirmation of sustained momentum. The latest developments reinforce this view, with renewed institutional buying and robust technical signals placing emphasis on whether Amgen can maintain its advance above $450.23 in the near term.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.